Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia

Pharmacopsychiatry

Volumn 40, Issue 2, 2007, Pages 47-52

  Xiang, Y T ^a,b,c   Weng, Y Z ^b   Leung, C M ^a   Tang, W K ^a   Ungvari, G S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SHATIN HOSPITAL   (Hong Kong)

Author keywords

Antipsychotic polypharmacy; China; Outpatients; Prescription patterns; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOSE RESPONSE; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SOCIOECONOMICS;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHINA; CULTURAL CHARACTERISTICS; DEMOGRAPHY; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INCOME; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; REGRESSION ANALYSIS; SCHIZOPHRENIA; URBAN POPULATION;

EID: 34247877562     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-970062     Document Type: Article

References (51)

1. APA. Diagnostic and Statistical Manual of Mental Disorders 4th ed. Washington: American Psychiatric Association, 1994
2. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676
3. Barnes TR, Curson DA: Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994; 10: 464-479
4. Binder RL, Kazamatsuri H, Nishimura T, McNiel DE: Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan. Am J Psychiatry 1987; 144: 1494-1496
5. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA: Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand 2006; 113: 135-141
6. Casey DE: Motor and mental aspects of acute extrapyramidal syndromes. Acta Psychiatr Scand Suppl 1994; 380: 14-20
7. Chan S, MacKenzie A, Ng DT, Leung JK: An evaluation of the implementation of case management in the community psychiatric nursing service. J Adv Nurs 2000; 31: 144-156
8. Chang IM: Anti-aging and health-promoting constituents derived from traditional oriental herbal remedies: information retrieval using the TradiMed 2000 DB. Ann N Y Acad Sci 2001; 928: 281-286
9. Chinese Medical Association. Guideline for the prevention and treatment of mental disorder. Beijing: China Medical Association, 2003
10. Chong MY, Tan CH, Fujii S, Yang SY, Ungvari GS, Si T et al: Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 2004; 58: 61-67
11. Chong SA, Sachdev P, Mahendran R, Chua HC: Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore. Aust N Z J Psychiatry 2000; 34: 988-991
12. Cohen J: Statistical Power Analysis for the Behavioral Sciences 2nd ed. New York NJ: Erlbaum Hillsdale, 1988
13. Covell NH, Jackson CT, Evans AC, Essock SM: Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002; 28: 17-29
14. Freudenreich O, Goff DC: Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106: 323-330
15. Hao YT, Fang JQ: The introduction and usage of WHOQOL instument in Chinese. Modern rehabilitation 2000; 4: 1127-1129
16. Harvey PD, Keefe RS: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158: 176-184
17. Huang CH, Yang SY, Yao J, Zhang YJ: Investigation on the combination of antipsychotics and artane. Health psychology journal 2003; 11: 60-61
18. Hugenholtz GW, Heerdink ER, Meijer WE, Stolker JJ, Egberts AC, Nolen WA: Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 2005; 38: 122-124
19. Humberstone V, Wheeler A, Lambert T: An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Aust N Z J Psychiatry 2004; 38: 240-245
20. Ito C, Kubota Y, Sato M: A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999; 53 (Suppl): S35-S40
21. Karow A, Schnedler D, Naber D: What would the patient choose? Subjective comparison of atypical and typical neuroleptics. Pharmacopsychiatry 2006; 39: 47-51
22. Kennedy NB, Procyshyn RM: Rational antipsychotic polypharmacy. Can J Clin Pharmacol 2000; 7: 155-159
23. Kilian R, Angermeyer MC: The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: an application of random effect regression models and propensity scores in an observational prospective trial. Qual Life Res 2005; 14: 1275-1289
24. Leucht S, Pitschel-Walz C, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68
25. Lobana A, Mattoo SK, Basu D, Gupta N: Quality of life in schizophrenia in India: comparison of three approaches. Acta Psychiatr Scand 2001; 104: 51-55
26. Nunley M: Why psychiatrists in India prescribe so many drugs. Cult Med Psychiatry 1996; 20: 165-197
27. Overall JE, Beller SA: The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. J Gerontol 1984; 39: 187-193
28. Percudani M, Barbui C, Fortino I, Petrovich L: Epidemiology of first- and second-generation antipsychotic agents in Lombardy, Italy. Pharmacopsychiatry 2005; 38: 128-131
29. Phillips MR, Lu SH, Wang RW: Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience. Am J Psychiatry 1997; 154: 1228-1234
30. Phillips MR, Xiong W, Zhao ZA: Issues Involved in the Use of Scales for the Assessment of Negative and Positive Symptoms in Psychiatric Patients. Wuhan, PRC: Hubei Science and Technology Publishing House, 1990
31. Remington G, Saha A, Chong SA, Shammi C: Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005; 19: 843-872
32. Rudnick A: The impact of coping on the relation between symptoms and quality of life in schizophrenia. Psychiatry 2001; 64: 304-308
33. Schuklenk U: Helsinki Declaration revisions. Issues Med Ethics 2001; 9: 29
34. Shafer A: Meta-analysis of the brief psychiatric rating scale factor structure. Psychol Assess 2005; 17: 324-335
35. Shen YC: Psychiatry. Beijing: People's medical publishing house, 2002
36. Sim K, Su A, Chan YH, Shinfuku N, Kua EH, Tan CH: Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore. Psychiatry Clin Neurosci 2004; 58: 324-329
37. Sim K, Su A, Fujii S, Yang SY, Chong MY, Ungvari GS et al: Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004; 58: 178-183
38. Sim K, Su A, Leong JY, Yip K, Chong MY, Fujii S et al: High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry 2004; 37: 175-179
39. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19
40. Song CF: Analysis the first use of antipsychotics in the outpatients with first-episode schizophrenia. Sichuan Ment Health 2001; 14: 153-155
41. Stahl S, Freudenreich O, Goff D: A successful antipsychotic combination trial. Quo Vadis? Acta Psychiatr Scand 2004; 110: 241-242
42. Stahl SM, Grady MM: A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004; 11: 313-327
43. Taylor D, Paton C, Kerwin R: The Maudsley Prescribing Guidelines. London: Martin Dunitz, 2003
44. Ungvari GS, Chiu HF, Lam LC, Pang AH, Chung DW, Li SW et al: Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol 1999; 19: 141-148
45. Ungvari GS, Chung YG, Chee YK, Fung-Shing N, Kwong TW, Chiu HF: The pharmacological treatment of schizophrenia in Chinese patients: a comparison of prescription patterns between 1996 and 1999. Br J Clin Pharmacol 2002; 54: 437-444
46. Weissman EM: Antipsychotic prescribing practices in the Veterans Healthcare Administration - New York metropolitan region. Schizophr Bull 2002; 28: 31-42
47. Weng YZ, Xu MJ, Li DL, Guo FY, Huang Q, Fu T: Assessment of expressed emotion in family members of schizophrenic patients in Beijing. Mod Rehabil 2001; 5: 39-42
48. WHO. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. World Health Organization heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness. Br J Psychiatry 1990; 156: 412
49. WHO. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995; 41: 1403-1409
50. WHO. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med 1998; 28: 551-558
51. Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663-667